Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Phenethylamine derivatives

4F-MPH

C14H18FNO2 CAS 1354631-33-6 Analytical reference material — not for human consumption
Preferred name
4F-MPH
IUPAC name
methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate
Parent CAS number (reference)
1354631-33-6
Molecular formula
C14H18FNO2
Molecular weight
251.3 g/mol
InChIKey
XISBAJBPDVRSPG-CHWSQXEVSA-N
PubChem
CID 52944002
Source
PubChem
Verified synonyms & catalog abbreviations
4-Fluoromethylphenidate 4FMPH 4F MPH threomethylphenidate-4F

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

4F-MPH

Stimulant (dopamine/norepinephrine reuptake inhibitor) Ring-fluorinated phenidate
Verified PubChem & CAS Identity C14H18FNO2 · CAS 1354631-33-6 · CID 52944002
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 251.30 g/mol
Peer-Reviewed & Agency Citations 3 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

4F-MPH is a fluorinated analogue of methylphenidate and a dopamine/norepinephrine reuptake inhibitor, not a substrate releaser like amphetamine. Fluorination increases potency relative to methylphenidate, which is why the PsychonautWiki common oral band is only 10–15 mg. The reference IUPAC is the (2R,2'R) threo form, methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate. The subjective feel is focused stimulation, anxiety at the top of the range, and a long residual tail rather than an entactogenic roll.

Biotransformation & Active Metabolites

Like methylphenidate, the ester can be hydrolyzed to the inactive ritalinic-acid analogue. It is not a prodrug of amphetamine and it is not isopropylphenidate.

Temporal Pharmacokinetics

Potent, functional NDRI stimulant. Focus and wakefulness, little serotonin warmth, a sharp anxiety edge when pushed, and hours of residual stimulation.

  1. Onset 30–60 minutes
  2. Peak Window 2–4 hours
  3. Total Window 4–8 hours
  4. Residual / Half-Life After-effects 5–10 hours. The ester hydrolysis product is not an active 'second wind'.

Threshold under 5 mg, light 5–10 mg, common 10–15 mg, strong 15–20 mg, heavy above 20 mg. The entire useful span is about 15 mg wide. mucosal common is 8–14 mg and shorter; it is harsher and not required to describe the oral window. A methylphenidate-sized dose is already a heavy 4F-MPH dose.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
under 5 mg
Cognitive & Sensory

A small increase in alertness.

Somatic & Autonomic

Slight dry mouth.

Light
5–10 mg
Cognitive & Sensory

Functional focus and wakefulness with little mood elevation.

Somatic & Autonomic

Appetite suppression and a mild pulse increase.

Common Reference
10–15 mg
Cognitive & Sensory

Clear stimulation, task focus, and talkativeness that can tip into scatter.

Somatic & Autonomic

Tachycardia, cold hands, bruxism, and sweating.

Strong
15–20 mg
Cognitive & Sensory

Anxiety, forced wakefulness, and irritable focus rather than better concentration.

Somatic & Autonomic

Pronounced vasoconstriction, tremor, and a long insomnia tail.

Heavy / Toxic Zone
20 mg+
Cognitive & Sensory

Agitation, paranoia, and compulsive repeated exposure.

Somatic & Autonomic

Hypertensive strain, chest discomfort, severe insomnia, and seizure risk with tramadol or an MAOI.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Blocking monoamine breakdown while a releaser or a catecholamine uptake inhibitor is active can produce a hypertensive crisis and, for the serotonergic members, serotonin toxicity.

25x-NBOMe and 25x-NBOH

Adds extreme vasoconstriction and seizure risk on top of an already raised heart rate and blood pressure.

Tramadol and DXM

Both lower the seizure threshold. Tramadol also adds serotonin reuptake inhibition, which is dangerous with the serotonergic releasers in this set.

Elevated Hazard — Avoid

Other stimulants, cocaine, and high-dose caffeine

Additive tachycardia, hypertension, bruxism, and post-session anxiety without restoring a faded peak.

Alcohol, opioids, and benzodiazepines

The stimulant hides sedation. When it drops, the depressant remains.

Caution / Receptor Attenuation

Other phenidates, including isopropylphenidate and methylphenidate

Additive norepinephrine/dopamine reuptake block. IPPH common is 15–25 mg and is not a top-up for 4F-MPH.

Acidic drinks or food changing absorption

May change how fast the oral dose arrives. It does not make a 20 mg dose a light one.

Structural Isomer & Sibling Comparison

4F-MPH is the potent fluorinated methylphenidate: common oral 10–15 mg, heavy above 20 mg, 4–8 hours plus a 5–10 hour tail. IPPH is the isopropyl ester, less sharp, common 15–25 mg, total about 3.5–6 hours. Methylphenidate tablet habits are larger than this compound's heavy line. Neither phenidate is an entactogen; 4-FA and 5-MAPB are the wrong family and the wrong interactions.

Physicochemical Stability & Storage

Form: White, off-white, or pale tan crystalline powder, shards, or clumps as the hydrochloride or another salt. Not a plant blend. · Hydrochloride salts dissolve in water and alcohols. Succinate salts of the benzofurans also dissolve in water but contain less active amine per milligram.

Airtight, cool, dry, and dark. Some salts are hygroscopic and clump. A clump is not a reason to guess the mass.

Cross-Tolerance & Dependence Profile

Stimulant tolerance with cross-tolerance to other NDRIs and amphetamines. Halves over roughly 3–7 days and approaches baseline in 1–2 weeks of abstinence. Psychological dependence and a crash of fatigue and low mood are expected. It is not an opioid withdrawal. Chasing the 2–4 hour peak with a second 10 mg is how the heavy zone is reached.

Comprehensive Analytical & Toxicological Monograph

4F-MPH (methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate; CAS 1354631-33-6, PubChem CID 52944002) is 4-fluoromethylphenidate supplied as pure powder or crystals (C14H18FNO2, 251.30 g/mol). The reference structure is the (2R,2'R) threo isomer. It is a dopamine/norepinephrine reuptake inhibitor, more potent than methylphenidate and not a serotonin releaser. PsychonautWiki oral bands are threshold under 5 mg, light 5–10 mg, common 10–15 mg, strong 15–20 mg, and heavy above 20 mg, over 4–8 hours with 5–10 hours of after-effects. A methylphenidate-sized amount is already heavy here. IPPH is a milder, shorter phenidate and not a milligram match. Do not combine with MAOIs, tramadol, other stimulants, or 25x-NBOMe.

Chemical Architecture & Structural Profile

4F-MPH (methyl (2R)-2-(4-fluorophenyl)-2-[(2R)-piperidin-2-yl]acetate) is a reference compound belonging to the Phenethylamine derivatives class, characterized by the molecular formula C14H18FNO2 and a molar mass of 251.3 g/mol. The parent molecule is indexed under CAS registry number 1354631-33-6 and in the NCBI PubChem database as CID 52944002 (Standard InChIKey: XISBAJBPDVRSPG-CHWSQXEVSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), 4F-MPH is indexed within the Substituted phenidates structural group. Substituted phenethylamine derivative; documented reference precautions highlight hazardous interactions with MAOIs, tramadol, and lithium salts. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)